Survivin-based treatment strategies for squamous cell carcinoma

Andrea Santarelli, Marco Mascitti, Lucio Lo Russo, Davide Sartini, Giuseppe Troiano, Monica Emanuelli, Lorenzo Lo Muzio

Research output: Contribution to journalReview article

10 Citations (Scopus)

Abstract

Survivin, an anti-apoptotic molecule abundantly expressed in most human neoplasms, has been reported to contribute to cancer initiation and drug resistance in a wide variety of human tumors. Efficient downregulation of survivin can sensitize tumor cells to various therapeutic interventions, generating considerable efforts in its validation as a new target in cancer therapy. This review thoroughly analyzes up-to-date information on the potential of survivin as a therapeutic target for new anticancer treatments. The literature dealing with the therapeutic targeting of survivin will be reviewed, discussing specifically squamous cell carcinomas (SCCs), and with emphasis on the last clinical trials. This review gives insight into the recent developments undertaken in validating various treatment strategies that target survivin in SCCs and analyze the translational possibility, identifying those strategies that seem to be the closest to being incorporated into clinical practice. The most recent developments, such as dominant-negative survivin mutants, RNA interference, anti-sense oligonucleotides, small-molecule inhibitors, and peptide-based immunotherapy, seem to be helpful for effectively downregulating survivin expression and reducing tumor growth potential, increasing the apoptotic rate, and sensitizing tumor cells to chemo- and radiotherapy. However, selective and efficient targeting of survivin in clinical trials still poses a major challenge.

Original languageEnglish
Article number971
JournalInternational Journal of Molecular Sciences
Volume19
Issue number4
DOIs
Publication statusPublished - Apr 1 2018

Fingerprint

Tumors
Squamous Cell Carcinoma
tumors
cancer
Neoplasms
Cells
neoplasms
sensitizing
Molecules
Chemotherapy
oligonucleotides
Antisense Oligonucleotides
Oligonucleotides
Radiotherapy
Therapeutics
chemotherapy
RNA
inhibitors
Peptides
Down-Regulation

Keywords

  • Inhibitor of apoptosis
  • Oral squamous cell carcinoma
  • Squamous cell carcinoma
  • Survivin

ASJC Scopus subject areas

  • Catalysis
  • Molecular Biology
  • Spectroscopy
  • Computer Science Applications
  • Physical and Theoretical Chemistry
  • Organic Chemistry
  • Inorganic Chemistry

Cite this

Santarelli, A., Mascitti, M., Lo Russo, L., Sartini, D., Troiano, G., Emanuelli, M., & Lo Muzio, L. (2018). Survivin-based treatment strategies for squamous cell carcinoma. International Journal of Molecular Sciences, 19(4), [971]. https://doi.org/10.3390/ijms19040971

Survivin-based treatment strategies for squamous cell carcinoma. / Santarelli, Andrea; Mascitti, Marco; Lo Russo, Lucio; Sartini, Davide; Troiano, Giuseppe; Emanuelli, Monica; Lo Muzio, Lorenzo.

In: International Journal of Molecular Sciences, Vol. 19, No. 4, 971, 01.04.2018.

Research output: Contribution to journalReview article

Santarelli, A, Mascitti, M, Lo Russo, L, Sartini, D, Troiano, G, Emanuelli, M & Lo Muzio, L 2018, 'Survivin-based treatment strategies for squamous cell carcinoma', International Journal of Molecular Sciences, vol. 19, no. 4, 971. https://doi.org/10.3390/ijms19040971
Santarelli, Andrea ; Mascitti, Marco ; Lo Russo, Lucio ; Sartini, Davide ; Troiano, Giuseppe ; Emanuelli, Monica ; Lo Muzio, Lorenzo. / Survivin-based treatment strategies for squamous cell carcinoma. In: International Journal of Molecular Sciences. 2018 ; Vol. 19, No. 4.
@article{93d0d1225d1d4d71a59fea162d99e0db,
title = "Survivin-based treatment strategies for squamous cell carcinoma",
abstract = "Survivin, an anti-apoptotic molecule abundantly expressed in most human neoplasms, has been reported to contribute to cancer initiation and drug resistance in a wide variety of human tumors. Efficient downregulation of survivin can sensitize tumor cells to various therapeutic interventions, generating considerable efforts in its validation as a new target in cancer therapy. This review thoroughly analyzes up-to-date information on the potential of survivin as a therapeutic target for new anticancer treatments. The literature dealing with the therapeutic targeting of survivin will be reviewed, discussing specifically squamous cell carcinomas (SCCs), and with emphasis on the last clinical trials. This review gives insight into the recent developments undertaken in validating various treatment strategies that target survivin in SCCs and analyze the translational possibility, identifying those strategies that seem to be the closest to being incorporated into clinical practice. The most recent developments, such as dominant-negative survivin mutants, RNA interference, anti-sense oligonucleotides, small-molecule inhibitors, and peptide-based immunotherapy, seem to be helpful for effectively downregulating survivin expression and reducing tumor growth potential, increasing the apoptotic rate, and sensitizing tumor cells to chemo- and radiotherapy. However, selective and efficient targeting of survivin in clinical trials still poses a major challenge.",
keywords = "Inhibitor of apoptosis, Oral squamous cell carcinoma, Squamous cell carcinoma, Survivin",
author = "Andrea Santarelli and Marco Mascitti and {Lo Russo}, Lucio and Davide Sartini and Giuseppe Troiano and Monica Emanuelli and {Lo Muzio}, Lorenzo",
year = "2018",
month = "4",
day = "1",
doi = "10.3390/ijms19040971",
language = "English",
volume = "19",
journal = "International Journal of Molecular Sciences",
issn = "1661-6596",
publisher = "MDPI AG",
number = "4",

}

TY - JOUR

T1 - Survivin-based treatment strategies for squamous cell carcinoma

AU - Santarelli, Andrea

AU - Mascitti, Marco

AU - Lo Russo, Lucio

AU - Sartini, Davide

AU - Troiano, Giuseppe

AU - Emanuelli, Monica

AU - Lo Muzio, Lorenzo

PY - 2018/4/1

Y1 - 2018/4/1

N2 - Survivin, an anti-apoptotic molecule abundantly expressed in most human neoplasms, has been reported to contribute to cancer initiation and drug resistance in a wide variety of human tumors. Efficient downregulation of survivin can sensitize tumor cells to various therapeutic interventions, generating considerable efforts in its validation as a new target in cancer therapy. This review thoroughly analyzes up-to-date information on the potential of survivin as a therapeutic target for new anticancer treatments. The literature dealing with the therapeutic targeting of survivin will be reviewed, discussing specifically squamous cell carcinomas (SCCs), and with emphasis on the last clinical trials. This review gives insight into the recent developments undertaken in validating various treatment strategies that target survivin in SCCs and analyze the translational possibility, identifying those strategies that seem to be the closest to being incorporated into clinical practice. The most recent developments, such as dominant-negative survivin mutants, RNA interference, anti-sense oligonucleotides, small-molecule inhibitors, and peptide-based immunotherapy, seem to be helpful for effectively downregulating survivin expression and reducing tumor growth potential, increasing the apoptotic rate, and sensitizing tumor cells to chemo- and radiotherapy. However, selective and efficient targeting of survivin in clinical trials still poses a major challenge.

AB - Survivin, an anti-apoptotic molecule abundantly expressed in most human neoplasms, has been reported to contribute to cancer initiation and drug resistance in a wide variety of human tumors. Efficient downregulation of survivin can sensitize tumor cells to various therapeutic interventions, generating considerable efforts in its validation as a new target in cancer therapy. This review thoroughly analyzes up-to-date information on the potential of survivin as a therapeutic target for new anticancer treatments. The literature dealing with the therapeutic targeting of survivin will be reviewed, discussing specifically squamous cell carcinomas (SCCs), and with emphasis on the last clinical trials. This review gives insight into the recent developments undertaken in validating various treatment strategies that target survivin in SCCs and analyze the translational possibility, identifying those strategies that seem to be the closest to being incorporated into clinical practice. The most recent developments, such as dominant-negative survivin mutants, RNA interference, anti-sense oligonucleotides, small-molecule inhibitors, and peptide-based immunotherapy, seem to be helpful for effectively downregulating survivin expression and reducing tumor growth potential, increasing the apoptotic rate, and sensitizing tumor cells to chemo- and radiotherapy. However, selective and efficient targeting of survivin in clinical trials still poses a major challenge.

KW - Inhibitor of apoptosis

KW - Oral squamous cell carcinoma

KW - Squamous cell carcinoma

KW - Survivin

UR - http://www.scopus.com/inward/record.url?scp=85044471929&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85044471929&partnerID=8YFLogxK

U2 - 10.3390/ijms19040971

DO - 10.3390/ijms19040971

M3 - Review article

C2 - 29587347

AN - SCOPUS:85044471929

VL - 19

JO - International Journal of Molecular Sciences

JF - International Journal of Molecular Sciences

SN - 1661-6596

IS - 4

M1 - 971

ER -